Radiopharmaceuticals and Practical Options at Each Center
| Parameter | 68Ga-DOTATOC | 18F-FDOPA | 18F-FDG | 111In-pentetreotide | 123I-MIBG |
| Hospital | Tenon | Tenon | Tenon | Cochin | Cochin |
| Modality | PET/CT | PET/CT | PET/CT | SPECT/CT | SPECT/CT |
| Radiopharmaceutical | 68Ga-DOTATOC (Iason) and GalliaPharm (Eckert & Ziegler) | Iasodopa (Iason) | Metatrace (Siemens) or Gluscan (AAA) | Octreoscan (Mallinckrodt) | 123I-MIBG (Mallinckrodt) or Adreview (GE Healthcare) |
| Physical half-life (min) | 68 | 110 | 110 | 4,032 (2.8 d) | 792 (13.2 h) |
| Scheduled injected activity | 1–2 MBq/kg BM | 2.5–3.5 MBq/kg BM | 2–3 MBq/kg BM | 185 MBq | 185 MBq |
| Scheduled interval between injection and imaging (min) | 45–90 | 10 (MTC) and 60 | 60–120 | 1,440 (24 h) | 240 and 1,440 (4 and 24 h) |
| Photonic ray for imaging (keV) | 511 | 511 | 511 | 245 and 171 | 159 |
BM = body mass; MTC = medullary thyroid cancer.